vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and OFG BANCORP (OFG). Click either name above to swap in a different company.
OFG BANCORP is the larger business by last-quarter revenue ($184.3M vs $94.9M, roughly 1.9× DYNAVAX TECHNOLOGIES CORP). OFG BANCORP runs the higher net margin — 30.3% vs 28.4%, a 1.9% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 0.9%). OFG BANCORP produced more free cash flow last quarter ($199.3M vs $32.6M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 2.8%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
OFG Bancorp, founded in 1964, is the financial holding company for Oriental Bank, located in San Juan, Puerto Rico. OFG offers a wide range of retail and commercial banking, lending and wealth management products, services and technology, primarily in Puerto Rico and the U.S. Virgin Islands through its principal subsidiaries: Oriental Bank, Oriental Financial Services LLC, and Oriental Insurance LLC. Its headquarters are located at Oriental Center, 254 Muñoz Rivera Avenue, San Juan, PR 00918....
DVAX vs OFG — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $184.3M |
| Net Profit | $26.9M | $55.9M |
| Gross Margin | — | — |
| Operating Margin | 22.4% | 25.7% |
| Net Margin | 28.4% | 30.3% |
| Revenue YoY | 17.7% | 0.9% |
| Net Profit YoY | 53.0% | 11.0% |
| EPS (diluted) | $0.21 | $1.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $184.3M | ||
| Q3 25 | $94.9M | $186.2M | ||
| Q2 25 | $95.4M | $182.4M | ||
| Q1 25 | $68.2M | $178.6M | ||
| Q4 24 | $72.0M | $182.7M | ||
| Q3 24 | $80.6M | $174.7M | ||
| Q2 24 | $73.8M | $179.8M | ||
| Q1 24 | $50.8M | $174.4M |
| Q4 25 | — | $55.9M | ||
| Q3 25 | $26.9M | $51.8M | ||
| Q2 25 | $18.7M | $51.8M | ||
| Q1 25 | $-96.1M | $45.6M | ||
| Q4 24 | $7.0M | $50.3M | ||
| Q3 24 | $17.6M | $47.0M | ||
| Q2 24 | $11.4M | $51.1M | ||
| Q1 24 | $-8.7M | $49.7M |
| Q4 25 | — | 25.7% | ||
| Q3 25 | 22.4% | 33.0% | ||
| Q2 25 | 15.1% | 36.1% | ||
| Q1 25 | -34.7% | 33.3% | ||
| Q4 24 | -2.3% | 28.9% | ||
| Q3 24 | 12.5% | 35.4% | ||
| Q2 24 | 7.0% | 39.6% | ||
| Q1 24 | -35.0% | 38.9% |
| Q4 25 | — | 30.3% | ||
| Q3 25 | 28.4% | 27.8% | ||
| Q2 25 | 19.6% | 28.4% | ||
| Q1 25 | -141.0% | 25.5% | ||
| Q4 24 | 9.8% | 27.6% | ||
| Q3 24 | 21.8% | 26.9% | ||
| Q2 24 | 15.4% | 28.4% | ||
| Q1 24 | -17.2% | 28.5% |
| Q4 25 | — | $1.27 | ||
| Q3 25 | $0.21 | $1.16 | ||
| Q2 25 | $0.14 | $1.15 | ||
| Q1 25 | $-0.77 | $1.00 | ||
| Q4 24 | $0.07 | $1.10 | ||
| Q3 24 | $0.12 | $1.00 | ||
| Q2 24 | $0.08 | $1.08 | ||
| Q1 24 | $-0.07 | $1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $1.0B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $534.1M | $1.4B |
| Total Assets | $946.5M | $12.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.0B | ||
| Q3 25 | $160.2M | $740.3M | ||
| Q2 25 | $99.1M | $851.8M | ||
| Q1 25 | $51.7M | $710.6M | ||
| Q4 24 | $95.9M | $591.1M | ||
| Q3 24 | $119.3M | $680.6M | ||
| Q2 24 | $112.5M | $740.4M | ||
| Q1 24 | $132.0M | $754.4M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | $534.1M | $1.4B | ||
| Q2 25 | $494.2M | $1.3B | ||
| Q1 25 | $530.9M | $1.3B | ||
| Q4 24 | $596.8M | $1.3B | ||
| Q3 24 | $681.4M | $1.3B | ||
| Q2 24 | $642.8M | $1.2B | ||
| Q1 24 | $618.5M | $1.2B |
| Q4 25 | — | $12.5B | ||
| Q3 25 | $946.5M | $12.2B | ||
| Q2 25 | $918.4M | $12.2B | ||
| Q1 25 | $945.9M | $11.7B | ||
| Q4 24 | $986.3M | $11.5B | ||
| Q3 24 | $1.1B | $11.5B | ||
| Q2 24 | $1.0B | $11.3B | ||
| Q1 24 | $986.6M | $11.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $217.7M |
| Free Cash FlowOCF − Capex | $32.6M | $199.3M |
| FCF MarginFCF / Revenue | 34.4% | 108.1% |
| Capex IntensityCapex / Revenue | 1.3% | 10.0% |
| Cash ConversionOCF / Net Profit | 1.26× | 3.90× |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $345.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $217.7M | ||
| Q3 25 | $33.8M | $39.5M | ||
| Q2 25 | $23.4M | $35.9M | ||
| Q1 25 | $-19.6M | $83.1M | ||
| Q4 24 | $53.0M | $252.5M | ||
| Q3 24 | $19.5M | $58.1M | ||
| Q2 24 | $10.7M | $95.1M | ||
| Q1 24 | $-16.7M | $61.0M |
| Q4 25 | — | $199.3M | ||
| Q3 25 | $32.6M | $35.5M | ||
| Q2 25 | $22.0M | $31.8M | ||
| Q1 25 | $-23.6M | $78.7M | ||
| Q4 24 | $49.5M | $231.2M | ||
| Q3 24 | $18.1M | $51.8M | ||
| Q2 24 | $9.9M | $90.4M | ||
| Q1 24 | $-17.4M | $54.8M |
| Q4 25 | — | 108.1% | ||
| Q3 25 | 34.4% | 19.1% | ||
| Q2 25 | 23.0% | 17.4% | ||
| Q1 25 | -34.6% | 44.1% | ||
| Q4 24 | 68.8% | 126.5% | ||
| Q3 24 | 22.5% | 29.6% | ||
| Q2 24 | 13.5% | 50.3% | ||
| Q1 24 | -34.3% | 31.4% |
| Q4 25 | — | 10.0% | ||
| Q3 25 | 1.3% | 2.1% | ||
| Q2 25 | 1.5% | 2.3% | ||
| Q1 25 | 5.8% | 2.4% | ||
| Q4 24 | 4.8% | 11.7% | ||
| Q3 24 | 1.7% | 3.6% | ||
| Q2 24 | 1.1% | 2.6% | ||
| Q1 24 | 1.5% | 3.5% |
| Q4 25 | — | 3.90× | ||
| Q3 25 | 1.26× | 0.76× | ||
| Q2 25 | 1.25× | 0.69× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | 7.52× | 5.02× | ||
| Q3 24 | 1.11× | 1.24× | ||
| Q2 24 | 0.94× | 1.86× | ||
| Q1 24 | — | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
OFG
Segment breakdown not available.
